Inovio Pharmaceuticals. has been granted a patent for nucleic acid molecules encoding synthetic consensus Survivin antigens. The patent includes vectors, compositions, and vaccines aimed at treating or preventing Survivin-expressing tumors, detailing specific nucleic acid sequences related to these antigens. GlobalData’s report on Inovio Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Inovio Pharmaceuticals, Personalized cancer vaccines was a key innovation area identified from patents. Inovio Pharmaceuticals's grant share as of July 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Nucleic acid molecules encoding synthetic consensus survivin antigens
The granted patent US12064473B2 encompasses claims related to specific nucleic acid molecules that encode various protein sequences. The first claim details a nucleic acid molecule that includes sequences encoding proteins identified as SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13. Additionally, it covers sequences that encode proteins exhibiting at least 95% identity to these sequences, with specific modifications involving the incorporation of alanine at designated positions (33, 47, and 83) relative to SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13. This claim highlights the potential for creating variants of these proteins while maintaining a high degree of sequence similarity.
The second claim similarly outlines a nucleic acid molecule comprising sequences that encode proteins represented by SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:8. It also includes sequences that encode proteins with at least 95% identity to these sequences, incorporating alanine at positions 51, 65, and 101 relative to SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:8. This claim emphasizes the structural modifications that can be made to the proteins while retaining significant sequence homology, potentially allowing for functional variations that could be relevant in various biotechnological or therapeutic applications.
To know more about GlobalData’s detailed insights on Inovio Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
